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Received August 10, 2015; accepted November 10, 2015AbstractBackground: Radiation recall pneumonitis (RRP) is a special form of radiation pneumonitis precipitated by certain pharmacological agents.
Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is an effective treatment for advanced nonsmall-cell lung cancer
(NSCLC) and has been reported as a potent radiation sensitizer. The incidence and general characteristics of EGFR-TKI-related RRP in patients
with NSCLC remain unclear.
Methods: Clinical records and serial chest images of consecutive patients with advanced NSCLC who had received thoracic radiotherapy (TRT)
and EGFR-TKI treatment were retrospectively reviewed. EGFR-TKI-related RRP was diagnosed according to history, clinical manifestations,
and radiographic characteristics. Potential risk factors were analyzed.
Results: In total, 160 patients with NSCLC who received EGFR-TKI after TRT were identified. Of these patients, seven (4.4%) developed
EGFR-TKI-related RRP. The median time interval between the end of radiotherapy and RRP was 124 days (range, 80e635 days) and that
between the initiation of EGFR-TKI and RRP was 43 days (range, 18e65 days). No risk factor for the development of RRP was identified except
that patients in whom EGFR-TKI was initiated within 90 days after the completion of radiotherapy had significantly higher rates of RRP than
those of patients who began receiving EGFR-TKI treatment after 90 days (21% vs. 2.1%, p ¼ 0.005).
Conclusion: In patients with NSCLC who have a history of TRT, treatment with EGFR-TKI may induce not only interstitial lung disease but also
RRP. Physicians should be aware of both unexpected adverse events when using EGFR-TKI.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Nonsmall-cell lung cancer (NSCLC) is a major cause of
cancer death. Definite thoracic radiotherapy (TRT), with or
without concurrent chemotherapy, is the treatment of choice
for patients with unresectable locally advanced NSCLC.1 One
of the most common treatment-related toxicities is radiation
pneumonitis, which typically occurs between 1 month and
6 months after the completion of radiotherapy.2,3 The clinicalsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
Table 1
Characteristics and treatment of all patients (n ¼ 160).
Demographics
Sex
Male 103 (64.4)
Female 57 (35.6)
Age (y) 68 (25e94)
Clinical stage at EGFR-TKI treatment
IIIA 10 (6.3)
IIIB 15 (9.4)
IV 135 (84.4)
ECOG PS
0e1 123 (76.9)
2 37 (23.1)
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with or without changes in pulmonary function. Radiation
recall pneumonitis (RRP) is a special form of radiation
pneumonitis (RP), which is an inflammatory reaction in a
previously irradiated area of lung tissue after application of a
pharmacological agent such as chemotherapy.4,5
In recent years, studies have shown that epidermal growth
factor receptor-tyrosine kinase inhibitor (EGFR-TKI), gefiti-
nib, erlotinib, and afatinib can provide significant benefits to
patients with advanced NSCLC.6e9 Patients with tumors that
had sensitive EGFR mutations and had been treated with
EGFR-TKI experienced longer progression-free survival and a
higher quality of life compared with those who had been
treated with standard chemotherapy.10e12 A major concern
during EGFR-TKI treatment is the development of interstitial
lung disease (ILD), which Inoue et al13 first reported in 2003.
Although rare, ILD is a potentially life-threatening compli-
cation of EGFR-TKI treatment. Studies have suggested that
prior radiotherapy is a risk factor for the development of
ILD.13,14
Both in vitro and in vivo studies have suggested that EGFR-
TKI not only enhances the antitumor activity of radiation but
also increases pulmonary toxicity.15e18 Furthermore, case re-
ports have discussed RRP after treatment with EGFR-
TKI.19e21 Previous studies have focused mostly on EGFR-
TKI-induced ILD; however, the incidence of EGFR-TKI-
related RRP remains unclear, and therefore requires further
investigation.
2. Methods
Smoking
Never smoker 81 (50.6)2.1. Patients and clinical data
Ever or current smoker 79 (49.4)
Histology
Adenocarcinoma 97 (60.6)
Squamous cell carcinoma 42 (26.3)
Others 21 (13.1)
Pre-existing ILD
Yes 24 (15.0)
No 136 (85.0)
FVC (L)a 2.56 (1.11e4.63)
FEV1 (L)a 1.84 (0.72e3.57)
Radiotherapy technique
2D Conventional TRT 10 (6.3)
3D Conformal TRT 150 (93.8)
Radiotherapy dose (Gy) 60 (20e76)
Mean lung dose (Gy)b 12.8 (1.1e26.4)
V5 (%)b 50 (5e92)
V20 (%)b 22 (2e54)
Concurrent chemotherapy during radiotherapy
Yes 58 (36.3)
No 102 (63.8)
EGFR-TKIWe retrospectively reviewed the medical and radiation
therapy records of patients with NSCLC who were treated
between 2002 and 2011 at Taipei Veterans General Hospital,
Taipei, Taiwan. Patients with advanced NSCLC who had
received TRT and EGFR-TKI (within 5 years after radio-
therapy) were screened. However, patients who had received
concurrent EGFR-TKI and radiotherapy or EGFR-TKI before
radiotherapy were excluded. The following demographic data
of patients were retrieved: age, sex, smoking history, Eastern
Cooperative Oncology Group performance status, pulmonary
function, histology type, and clinical stage. Serial chest images
of each patient were reviewed. The patients were followed-up
until October 31, 2013, or death. This study was approved by
the Institutional Review Board of Taipei Veterans General
Hospital and was conducted in accordance with the Declara-
tion of Helsinki.Gefitinib 52 (32.5)
Erlotinib 108 (67.5)2.2. Radiotherapy parameters
Data are presented as n (%) or median (range).
EGFR-TKI ¼ epidermal growth factor receptor-tyrosine kinase inhibitor;
ILD ¼ interstitial lung disease; FEV1 ¼ forced expiratory volume in 1 second;
FVC ¼ forced vital capacity; TRT ¼ thoracic radiotherapy; 2D ¼ two
dimensional; 3D ¼ three dimensional.
a Data available in 132 cases.
b Data available in 139 cases.The following dosimetric parameters were generated from
the dose-volume histogram of the patients' radiotherapy
treatment planning: (1) the mean lung dose (MLD), which is
the average radiation dose of the whole-lung volume; and (2)
the V5 and V20, which correspond to the percentages of thelung volume receiving a radiation dose of more than 5 Gy
and 20 Gy, respectively, during the entire course of radio-
therapy. The MLD, V5, and V20 are the most commonly
applied parameters for evaluating the possibilities of
radiotherapy-induced pneumonitis. These parameters were
calculated according to the dose distribution in the bilateral
whole-lung volume minus the planned target volume. All the
data were obtained and manipulated using the Eclipse
Treatment Planning System (Varian Medical Systems, Palo
Alto, CA, USA).2.3. Definition of EGFR-TKI-related RRP and classical
EGFR-TKI-induced ILDThe diagnosis of EGFR-TKI-related RRP was based on the
following criteria: (1) use of EGFR-TKI treatment after the
Fig. 1. Patient disposition. EGFR-TKI ¼ epidermal growth factor receptor-tyrosine kinase inhibitor; ILD ¼ interstitial lung disease; NSCLC ¼ nonsmall-cell lung
cancer; RRP ¼ radiation recall pneumonitis; TRT ¼ thoracic radiotherapy.
Table 2
Patient demographics in radiation recall pneumonitis cases.
Case Sex Age Smoking status Histology Stage EGFR-TKI PS Pre-existing ILD
1 F 56 Never Adenocarcinoma IV Gefitinib 0 No
2 M 88 Never Adenocarcinoma IIIB Erlotinib 2 Yes
3 F 63 Never Adenocarcinoma IV Erlotinib 1 No
4 M 83 Ever NSCLC IV Gefitinib 3 No
5 M 84 Ever Carcinoma IV Gefitinib 2 No
6 M 70 Ever Squamous IIIB Erlotinib 1 No
7 M 70 Ever Squamous IV Erlotinib 1 No
EGFR-TKI ¼ epidermal growth factor receptor-tyrosine kinase inhibitor; F ¼ female; ILD ¼ interstitial lung disease; M ¼ male; NSCLC ¼ nonsmall cell lung
cancer; PS ¼ ECOG performance status.
Table 3
Clinical characteristics in radiation recall pneumonitis cases.
Case T1 (d) T2 (d) Symptoms RRP
Grade
Management Outcome
Hold TKI Steroid
1 47 33 Dyspnea, cough 3 Yes Yes Alive
2 49 57 Cough 2 Yes No Alive
3 69 57 Nil 1 No No Alive
4 610 25 Dyspnea 3 No Yes Alive
5 106 18 Dyspnea, cough 2 No No Alive
6 32 65 Dyspnea, cough 3 Yes Yes Alive
7 155 43 Cough 2 No No Alive
EGFR-TKI ¼ epidermal growth factor receptor-tyrosine kinase inhibitor;
T1 ¼ time interval between the end of thoracic radiation and the beginning of
EGFR-TKI; T2 ¼ time interval between the beginning of EGFR-TKI and the
occurrence of RRP.
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piratory symptoms during EGFR-TKI treatment; (3) acute
radiographic changes including ground-glass opacity or
consolidation within the prior radiation area; and (4) the
radiological examination of the chest before EGFR-TKItreatment showing no pneumonitis change. All information was
independently reviewed by two pulmonologists and one radi-
ologist, and consensus was reached to confirm the diagnosis.
The grade of RRP was classified according to the National
Cancer Institute's Common Terminology Criteria for Adverse
Events, version 4.0: Grade 1 pneumonitis is asymptomatic and
diagnosed according to radiographic findings only; Grade 2
pneumonitis is symptomatic and requires medical intervention;
Grade 3 pneumonitis is severely symptomatic, limiting self-care
daily activities, and necessitates oxygen; Grade 4 pneumonitis is
life-threatening and requires urgent intervention (tracheostomy
or intubation); and Grade 5 pneumonitis is lethal. The diagnosis
of classical EGFR-TKI-induced ILD was based on previously
published criteria: (1) new onset of respiratory symptoms during
EGFR-TKI treatment; (2) characteristic radiological findings on
chest plain film or computed tomography scan; and (3) exclu-
sion of pulmonary infection, lymphangitis carcinomatosis, and
RP.22 Preexisting ILD was defined as peripheral reticulation at
the bilateral lung base on chest computed tomographic images,
which were obtained before radiotherapy.
251C.-L. Chiang et al. / Journal of the Chinese Medical Association 79 (2016) 248e2552.4. Statistical analysisStatistical analyses were conducted and plots constructed
using SPSS statistics 18.0 (SPSS Inc., Chicago, IL, USA). The
association between the potential factors and the occurrence of
RRP was analyzed using Fisher's exact test. Radiotherapy
dosimetric parameters were compared between groups using
the ManneWhitney U test. A p value < 0.05 was considered
statistically significant.
3. Results
A total of 763 patients who had received TRT for advanced
NSCLC between 2002 and 2011 in this institute were identi-
fied. Of those patients, 160 received EGFR-TKI treatment
after the completion of radiotherapy. Demographic data of
these patients are summarized in Table 1. Most of the patients
were men (64.4%), approximately half were nonsmokers
(50.6%), and some of them had pre-existing ILD (15%). Of
the 160 patients, 150 received three-dimensional conformal
radiotherapy. The median radiation dose was 60 Gy (range,Fig. 2. A representative case with epidermal growth factor receptor-tyrosine kinas
histogram of thoracic radiotherapy; (B) computed tomography (CT)-based three di
radiotherapy; (D) CT scan after the end of radiotherapy; and (E) radiation pneum
therapy. LL ¼ left lung; RL ¼ right lung; TL ¼ total lung.20e76 Gy). A total of 58 patients (36.3%) underwent radio-
therapy with concurrent chemotherapy. The median interval
between the completion of radiotherapy and EGFR-TKI was
7.4 months (range, 0.2e55 months). Radiotherapy dosimetric
parameters (MLD, V5, and V20) were available for 139 pa-
tients (87%).
In total, acute interstitial pneumonitis after TRT was iden-
tified in 20 patients. Based on the radiographic features,
clinical manifestations, and treatment history, six patients
were identified as having chemotherapy-related RRP. In 14
patients with interstitial pneumonitis during EGFR-TKI
treatment, the pneumonitis was confined to the prior radia-
tion field and was then considered EGFR-TKI-related RRP in
seven cases (4.4%). The pneumonitis was bilateral and
randomly distributed in the remaining seven patients (4.4%),
who were then diagnosed with classical EGFR-TKI-induced
ILD (Fig. 1). The demographics and clinical characteristics
of the patients with EGFR-TKI-related RRP are listed in
Tables 2 and 3, respectively. The median duration of EGFR-
TKI treatment at the occurrence of RRP was 43 days (range,
18e65 days); for the development of classical ILD, it wase inhibitor-related radiation recall pneumonitis (Case 3): (A) the dose-volume
mensional-conformal radiotherapy plan; (C) CT scan of chest obtained before
onitis induced by erlotinib, which developed 126 days after the end of radio-
Table 4
Risk factor analysis for the occurrence of epidermal growth factor receptor-
tyrosine kinase inhibitor (EGFR-TKI)-related radiation recall pneumonitis
(RRP).
Non-RRP (%)
n ¼ 153
RRP (%)
n ¼ 7
p
Type of EGFR-TKI 0.683
Gefitinib 49 (32.0) 3 (42.9)
Erlotinib 104 (68.0) 4 (57.1)
Sex >0.99
Male 98 (64.1) 5 (71.4)
Female 55 (35.9) 2 (28.6)
Age (y) >0.99
70 92 (60.1) 4 (57.1)
>70 61 (39.9) 3 (42.9)
Smoking status 0.718
Never 78 (51.0) 3 (42.9)
Ever 75 (49.0) 4 (57.1)
Histology 0.435
Adenocarcinoma 94 (61.4) 3 (42.9)
Others 59 (38.6) 4 (57.1)
Performance status 0.202
0e1 119 (77.8) 4 (57.1)
2 34 (22.2) 3 (42.9)
Pre-existing ILD >0.99
Yes 23 (15.0) 1 (14.3)
No 130 (85.0) 6 (85.7)
FEV1a >0.99
2 L 49 (38.9) 2 (33.3)
<2 L 77 (61.1) 4 (66.7)
FEV1/FVCa 0.665
70% 86 (68.3) 5 (83.3)
<70% 40 (31.7) 1 (16.7)
3D Conformal TRT 0.063
Yes 145 (94.8) 5 (71.4)
No 8 (5.2) 2 (28.6)
Concurrent chemotherapy 0.423
Yes 57 (37.3) 1 (1.7)
No 96 (62.7) 6 (85.7)
TRT dose 0.250
60 Gy 84 (54.9) 2 (28.6)
<60 Gy 69 (45.1) 5 (71.4)
Mean lung doseb >0.99
>20 Gy 8 (6.0) 0 (0)
20 Gy 126 (94.0) 5 (100)
V5 (%)b 0.587
>65 31 (23.1) 0 (0)
65 103 (76.9) 5 (100)
V20 (%)b 0.584
>30 29 (21.6) 0 (0)
30 105 (78.4) 5 (100)
Time interval between
TRT and EGFR-TKI
0.005
<90 d 16 (10.5) 4 (57.1)
90 d 137 (89.5) 3 (42.9)
FEV1 ¼ forced expiratory volume in 1 second; FVC ¼ forced vital capacity;
ILD ¼ interstitial lung disease; TRT ¼ thoracic radiotherapy.
a Data available in 132 cases.
b Data available in 139 cases.
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TKI related RRP was shown in Fig. 2.
Four patients (57%) with Grades 1 and 2 RRP and three
with Grade 3 RRP required hospitalization. Systemic steroids
were administered to patients with Grade 3 RRP; EGFR-TKI
treatment was aborted in two and continued in one patient.
In all patients, symptoms and radiographic abnormalities
improved in 2 weeks. In four patients with Grades 1 and 2
RRP, only supportive care was provided. EGFR-TKI treatment
was discontinued in one patient and continued in three patients
whose symptoms and radiographic changes remained stable.
None of these seven patients succumbed to RRP during the
study period. One patient with Grade 3 RRP was rechallenged
with the same EGFR-TKI after the episode and developed
bilateral interstitial pneumonitis. In patients with classical
EGFR-TKI-induced ILD, six of the seven patients developed
severe pneumonitis and required hospitalization. The mortality
rate was 71.4% despite aggressive medical treatment.
The occurrence of EGFR-TKI-related RRP was not asso-
ciated with sex, age, performance status, smoking history,
preexisting ILD, baseline pulmonary function, or type of
EGFR-TKI (all p > 0.05; Table 4). Regarding the timing of
EGFR-TKI treatment, EGFR-TKI-related RRP was more
common in patients treated with EGFR-TKI within 90 days
after the completion of radiotherapy compared with those who
began receiving treatment later (20% vs. 2.1%; p ¼ 0.005).
Development of classic EGFR-TKI-induced ILD after radio-
therapy showed borderline significant associations with male
sex ( p ¼ 0.051), poor performance status ( p ¼ 0.051), and
pre-existing ILD ( p ¼ 0.069).
Regarding the radiotherapy dosimetric parameters, no dif-
ference was observed between patients with and without
EGFR-TKI-related RRP or classical ILD except that patients
with EGFR-TKI-related RRP had a slightly lower V20
( p ¼ 0.051) than those without. By contrast, the occurrence of
chemotherapy-related RRP seemed to be associated with
higher V5 ( p ¼ 0.012) and MLD ( p ¼ 0.068; Fig. 3).
4. Discussion
Although uncommon, ILD is a potentially fatal complica-
tion of EGFR-TKI treatment. In this study, we showed that
EGFR-TKI might also induce another form of interstitial
pneumonitis, RRP, in patients who had received prior TRT. In
patients with mild symptoms, only supportive management
was required, whereas in those with moderate symptoms,
hospitalization and systemic steroid treatment were necessary.
RP is a common side effect of TRT, and the incidence of
RP correlates with radiation dose. A previous report showed
that V20 greater than 30% was significantly associated with
Grade 2 or greater RP in lung cancer patients who received
concurrent chemoradiation.23 Oh et al24 also reported that
MLD was the only significant factor predictive of RP and the
risk of RP was high if the MLD > 16.1 Gy. The diagnosis of
RP alone is less likely in our seven patients because none of
the patients had V20 > 25% or MLD > 15 Gy. Radiation
recall is a special form of RP characterized by acuteinflammation confined to a previously irradiated area, occurs
months or years after radiation treatment, and is triggered by
the administration of certain pharmacologic agents.4 Several
precipitating agents have been reported to be responsible for
radiation recall. Chemotherapeutics are the most common;
Fig. 3. Mean lung dose, V5, and V20 in patients with classical epidermal growth factor receptor-tyrosine kinase inhibitor induced interstitial lung disease (EGFR-
TKI-induced ILD), EGFR-TKI-related radiation recall pneumonitis (RRP), and chemotherapy-related RRP. *p < 0.05. **p < 0.1. ***p > 0.1.
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agents, have also been mentioned.25,26 EGFR-TKI is an
effective treatment for patients with advanced NSCLC and is
being used increasingly nowadays. When radiotherapy is
followed by EGFR-TKI, subclinical damage from irradiation
may be uncovered and manifest clinically as RRP. Previous
case reports have shown that EGFR-TKI could also induce
RRP.19e21 To our knowledge, this study is the first to sys-
tematically evaluate the incidence and risk factors of EGFR-
TKI-related RRP.
Several patient-specific factors (e.g., age, smoking history,
performance status, preexisting lung disease, and pulmonary
function) and treatment-specific factors (e.g., MLD, V5, and
V20) have been proposed as potential predictors of RP.2
However, no factor has been consistently reported to be
associated with RRP. In this study, we found no factors
significantly associated with EGFR-TKI-related RRP. How-
ever, interestingly, it seemed that higher normal lung radiation
exposure (represented by V5 and MLD) was associated with
an increased risk of chemotherapy-related RRP.
The mechanism of RRP remains unclear. Stem cells in the
irradiated area may have increased sensitivity or may display a
“remembered” reaction to subsequent treatment. Vascular re-
actions and idiosyncratic drug hypersensitivity phenomena arealso possible hypotheses.4,27 The difference in action between
cytotoxic chemotherapy and EGFR-TKI may provide a clue to
elucidate the mechanism of RRP. Further study is necessary to
investigate this issue.
Although RRP seems unpredictable, previous studies sug-
gest that the risk is higher if the time interval between the
completion of radiotherapy and initiation of chemotherapy is
short.4 Our study results were in agreement with this notion. In
this series, the incidence of EGFR-TKI-related RRP was up to
20% in patients who began receiving EGFR-TKI within
90 days after radiotherapy. By contrast, it was only 2.1% in
patients who were treated with EGFR-TKI 90 days after
radiotherapy. Moreover, two other patients developed classical
EGFR-TKI-induced ILD during this period. Together, six out
of 20 patients (30%) who received EGFR-TKI < 90 days after
radiotherapy developed some type of acute interstitial pneu-
monia. Therefore, because of the potential morbidity and
mortality, physicians should carefully evaluate the risks and
benefits of initiating EGFR-TKI treatment for patients who
have just completed TRT in the past 3 months.
Management of radiation recall depends on the affected
organ system and the severity of the reaction. In some cases,
radiation recall may resolve spontaneously and only a close
observation may be required.4 Withhold of the precipitating
254 C.-L. Chiang et al. / Journal of the Chinese Medical Association 79 (2016) 248e255agents and administration of systemic steroid may be needed if
pneumonitis of Grade 3 or above develops. Ding et al5 re-
ported an improvement in symptoms and in chest images for
all 12 patients with chemotherapy-induced RRP after aborting
treatment with precipitating agents and administering systemic
steroids. In our study, four of the seven patients with RRP
continued to be treated with EGFR-TKI, with or without a
short course of systemic steroid treatment. All patients
recovered from the episodes, which is in agreement with
previous reports that concluded that the prognosis of RRP is
generally favorable when it is diagnosed at an early
stage.5,20,21 By contrast, classical EGFR-TKI-induced ILD has
a relatively high mortality rate.28,29
In patients who had radiation recall, rechallenge with the
precipitating drug did not always elicit a reaction.4 The
evidence of rechallenge in lung cancer patients with RRP is
scarce. In Ding et al's5 series, four patients were rechal-
lenged with the same chemotherapy drugs with concomitant
steroid treatment, and none showed recurrence. However,
one patient in our series was rechallenged with the same
EGFR-TKI, and pneumonitis recurred and progressed to
bilateral lungs. Therefore, physicians should find a balance
between the severity of the underlying malignancy and the
efficacy and the potential toxicity of the agents considered
(Fig. 3).
The study has several limitations. Firstly, it was a retro-
spective study and some selection bias might have existed.
However, to the best of our knowledge, it is the only study to
estimate the incidence of EGFR-TKI-related RRP in patients
with NSCLC after TRT. Secondly, our definitions of EGFR-
TKI-related ILD and RRP are arbitrary. To the best of our
knowledge, there is no published criterion to differentiate
these two types of interstitial pneumonitis objectively. Our
definition of RRP, which was regularly used in previous re-
ports, is a pneumonitis that is elicited by some pharmacolog-
ical agent and is confined to a previously irradiated area.
However, classic EGFR-TKI related ILD is usually diffusely
distributed in both lungs and is not related to radiotherapy.
Also, based on our study, the severities of these two types of
pneumonitis are different. All patients with RRP recovered
from the episodes, but EGFR-TKI-induced ILD carried a high
mortality rate. More clinical studies are necessary to verify our
results.
In conclusion, this study showed that in patients with
NSCLC who have a history of TRT, treatment with EGFR-TKI
may induce not only interstitial lung disease but also RRP. The
RRP risk is 10-fold higher when the interval between the
completion of radiotherapy and the initiation of EGFR-TKI
is < 90 days. Physicians should be aware of both of these
unexpected adverse events and consider them when evaluating
the risks and benefits of EGFR-TKI after TRT.
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